Home
NewsNewsLuna and Kindbody are redefining Intelligence in Fertility Care through a strategic partnership that integrates wearable biomarker tracking into clinical pathways. By capturing real-time physiological data, the collaboration enables personalised insights, enhances decision-making, and creates a more connected, data-driven fertility journey for patients and care providers alike.
On March 17, 2026, healthtech innovator Luna and fertility benefits provider Kindbody announced a strategic partnership aimed at transforming women’s health through enhanced data-driven Intelligence in Fertility Care. This collaboration is designed to provide unprecedented clarity and personalisation for individuals navigating the complexities of the fertility journey.
Luna, recognised for developing advanced smart wearables, will integrate its biomarker tracking technology into Kindbody’s comprehensive fertility and family-building platform. This integration addresses a critical gap in reproductive health: the fact that intricate physiological shifts, such as changes in temperature, recovery, sleep, stress, and hormonal rhythms, primarily occur outside of a doctor's office. By bringing these daily signals into focus, the partnership offers patients a deeper understanding of their own bodies while providing Kindbody’s clinical teams with a contextual, holistic view of each individual’s health.
Amit Khatri, Founder of Luna, emphasised the human element of this technological advancement. “The conception journey is one of the most meaningful and complex chapters in a person's life, and it deserves both deep empathy and deep intelligence,” said Khatri. “By uniting Luna's continuous biomarker sensing with Kindbody's world-class clinical expertise, we are giving patients a clearer window into their bodies and giving physicians a new dimension of insight that can elevate the entire care experience. This partnership represents the future of reproductive health: connected, personalised, and profoundly human."
Kindbody, which operates a national network of signature clinics and provides virtual care, offers a wide array of services, including IVF, egg freezing, donor care, and LGBTQ+ fertility support. The company’s mission is to make high-quality reproductive care more accessible and equitable. Through this partnership, Luna’s technology, including the Luna ring, will be made available within the Kindbody ecosystem to support patients seeking a more connected path toward parenthood.
David Stern, CEO of Kindbody, highlighted the clinical value of the collaboration. “This partnership with Luna represents a significant step forward in making fertility care smarter and more personalised," said Stern. “By leveraging data-driven insights, we can better support patients and providers alike, ensuring every decision is informed, effective, and centred on the needs of those on their fertility journey."
At the heart of Luna’s contribution is LifeOS, an adaptive health operating system that interprets data from the Luna Ring to deliver real-time guidance on energy, recovery, and women’s health. Kindbody continues to expand its reach, offering benefit solutions for employers and health plans while covering everything from menopause to male fertility and holistic well-being. Together, the two companies aim to move precision health from an aspirational concept to a standard of care.
apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.
Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.
TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.
CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.
Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.
UNC Fertility has announced its plans for Collaboration with IVI RMA North America to bring best clinical and operational best practices across the region, expanding access to cutting-edge fertility treatments and research.
Alife Health has secured FDA clearance for Embryo Predict, its AI-powered embryo assessment tool for IVF. Backed by a 440-patient, seven-center randomized clinical trial, the platform delivers data-driven embryo selection insights to embryologists across the U.S., Europe, and the U.K., addressing longstanding variability in clinical decision-making.
